The determination of clinical stage in hairy cell leukemia is hampered by the lack of common criteria. Furthermore, clinical stages in which the disease should be treated have not yet been defined. In this paper we propose common criteria for the clinical staging of all hairy cell leukemia patients (treated or untreated), as well as for the assessment of responses to therapy. These criteria are absence or presence of disease-related symptoms and disease progression. Based on these criteria we propose that hairy cell leukemia patients in the most favorable stage of the functional system, non-symptomatic Stable Disease (nsSD), do not require treatment. Only in patients with disease-related symptoms and/or signs of disease progression is treatment justified and necessary. No symmetry was observed between the functional stages and Jansen’s stages. For evaluation of responses to treatment, our stages were more sensitive than the Leeds criteria. Experimental evidence enables the differentiation of patients with non-symptomatic stable disease from those with symptomatic and/or progressive disease.

Keywords:
Hairy cell leukemia, clinical staging, criteria for treatment
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.